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Morisky scaleAbstract Controlling hypertension is essential in cardiovascular diseases. Poor
medication adherence is associated with poor disease outcomes, waste of
healthcare resources, and contributes to reduced blood pressure control. This study
evaluates treatment adherence to antihypertensive therapy in Lebanese hyperten-
sive patients by estimating the proportion of adherent hypertensive patients
using a validated tool and investigates what factors predict this behavior. A
questionnaire-based cross-sectional study was conducted on a random sample of
210 hypertensive outpatients selected from clinics located in tertiary-care hospitals
and from private cardiology clinics located in Beirut. Adherence level was measured
using a validated 8-item Modified Morisky Medication Adherence Scale (MMMAS).
Among 210 patients, 50.5% showed high adherence, 27.1% medium adherence,
and 22.4% low adherence to medication. Mean MMMAS score was 6.59 ± 2.0. In
bivariate analyses, having controlled blood pressure (p = 0.003) and taking a combi-
nation drug (p = 0.023) were predictors of high adherence. Forgetfulness (p < 0.01),
complicated drug regimen (p = 0.001), and side effects (p = 0.006) were predictors
of low adherence after multiple liner regression. Logistic regression results showed
that calcium channel blockers (p = 0.030) were associated with increased adherence
levels. In conclusion, developing multidisciplinary intervention programs to address
the factors identified, in addition to educational strategies targeting healthcare
providers, are necessary to enhance patient adherence.
ª 2015 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Hypertension is a worldwide epidemic causing 7.1
million premature deaths each year and accounting
for 13% of all deaths globally [1]. Kearney et al. [2]
reported that overall prevalence of hypertension in
2000 was estimated to be 26.4% of the world
population and predicted that the burden of hyper-
tension would increase by 60% to approximately
1.56 billion in the year 2025. Also, hypertension
results in an economic burden of $47.5 billion
annually in direct medical expenses and $3.5 billion
each year in lost productivity [3].
According to the Seventh Report of the Joint
National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure
(JNC 7), hypertension is defined as a systolic blood
pressure (SBP) of 140 mmHg or higher, or a diastolic
blood pressure (DBP) of 90 mmHg or higher [1].
Hypertension is reported to be the leading cause
of cardiovascular disease worldwide [4].
Additionally, uncontrolled blood pressure (BP)
increases the risk of ischemic heart disease three-
to fourfold [5] and overall cardiovascular risk by
two-to threefold [6].
Among hypertensive patients who have poor BP
control, poor drug adherence is one of the causes
and accounts for an increasingly significant and
substantial public health burden [7]. Only 29% of
hypertensive patients in the United States achieve
adequate control and even fewer have been
reported in Canada and Europe (17% and 610%,
respectively) [8].
The term ‘‘adherence’’ is defined by the World
Health Organization (WHO) as the extent to which
a persons behavior taking medication, following a
diet, and/or executing lifestyle change corre-
sponds with agreed recommendations from a
health care provider [9]. The WHO describes poor
adherence as the most important cause of uncon-
trolled blood pressure [9] and estimates that
50–70% of people do not take their antihyperten-
sive medication as prescribed [10].
In a meta-analysis of literature on medication
nonadherence rates in the elderly, it was shown
that from 29% to 59% of outpatients do not take
medications as prescribed [11]. In another study
done on hypertensive patients in primary health
care centers and hospitals in Saudi Arabia, 53%
were found to be adherent and, consequently,
the mean SBP and DSB were found to be signifi-
cantly lower in adherent patients relative to those
nonadherent [12].
Numerous factors influence treatment adher-
ence, including demographic characteristics(gender, age, education, etc.), psychosocial fac-
tors (quality of life), socioeconomic status and dis-
ease severity, class of drug prescribed, patient
understanding of disease and importance of treat-
ment, co-morbid medical conditions, patient–
healthcare provider relationship, drug cost, forget-
fulness, and presence of psychological problems,
specifically depression [13–16].
Based on this, our study objective is to evaluate
treatment adherence to antihypertensive therapy
in Lebanese hypertensive patients by estimating
the proportion of adherent hypertensive patients
using a validated tool and to investigate what fac-
tors predict this behavior.
2. Methods
2.1. Patients and methods
A cross-sectional design utilizing a convenient sam-
ple and a well-designed questionnaire was adopted
to address the study objective. Patients recruited
for this study were randomly selected from those
visiting the external (outpatient) clinics located
in tertiary care hospitals and from private cardiol-
ogy clinics located in Beirut. In fact, interviewers
visited the location on randomly selected dates
and recruited all patients present in these clinics.
An oral informed consent was obtained from
each patient. All patients interviewed agreed to
participate in this study. The Institutional Review
Board of the Lebanese University stated that
approval was not necessary, since the study was
an observational one and not experimental, clini-
cal, or interventional.
2.2. Inclusion and exclusion criteria
Eligible patients were Lebanese adult outpatients
(P18 years). They were diagnosed with essential
(primary) hypertension by a cardiovascular physi-
cian and taking at least one antihypertensive med-
ication. Patients with co-existing medical
conditions were also included. Excluded subjects
were those with secondary hypertension, pregnant
women, or taking other drugs that could increase
BP. Hypertensive patients taking no medication
were also excluded.
2.3. Sample size
We used the following formula for sample size cal-
culation: n ¼ Z2:pð1pÞ
d2
, where Z is a standard normal
variate (Z = 1.96 when the confidence interval is
95%), p is the expected proportion of outcome in
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absolute accuracy or precision [17]. Based on a pre-
vious study where 16% of the population were
highly adherent (Morisky score of 8) [18], we calcu-
lated a minimal sample size of 207 that would be
required to give a 95% probability of measuring
the prevalence of high adherence with 5%
accuracy.
2.4. Data collection
Data were collected using a structured question-
naire composed of different sections chosen and
organized based on a thorough review of similar lit-
erature. The questionnaire was administered by
trained interviewers in the Arabic language for
ease of patient comprehension. The tool was pilotTable 1 Sociodemographic characteristics (n = 210).
Variables
Age
Gender
Males
Females
Body mass index
Normal weight
Overweight
Obese
Marital status
Single
Married
Divorced/widowed
Education level
Illiterate
Elementary
Intermediate
Secondary
University
Employment status
Unemployed
Employed/Self-employed
Retired
Monthly income
500,000–1,000,000
1,000,000–2,000,000
>2,000,000
Working hours
3–7
8–16
Having care provider at home
Having medical insurance
SD = standard deviation.tested on 30 patients who were not included in the
final study sample.
The questionnaire extracted information regard-
ing sociodemographic characteristics, lifestyle
characteristics, patient healthcare behaviors,
patient disease status, patient–healthcare provider
relationship, and patient medication adherence
using an 8-item modified Morisky Medication
Adherence Scale (8-MMMAS).
Trained investigators measured BP using aneroid
sphygmomanometers and stethoscopes in all
patients after they were in the resting state for
10 min and in a seated position with the right arm
placed at the level of the heart. Controlled hyper-
tension was defined as a BP reading <140 systolic or
<90 diastolic mmHg at the time of data collection
irrespective of measurements at other times. BPMean ± SD/n (%)
59.33 ± 12.201
85 (40.5)
125 (59.5)
51 (24.3)
103 (49)
56 (26.7)
11 (5.2)
170 (81)
29 (13.8)
30 (14.3)
66 (31.4)
55 (26.2)
23 (11)
36 (17.1)
132 (62.9)
57 (27.1)
21 (10)
95(45.2)
85 (40.5)
30 (14.3)
22 (10.5)
35 (16.7)
173 (82.4)
132 (62.9)
160 M. Yassine et al.readings P140 systolic or P90 diastolic mmHg are
referred to as uncontrolled hypertension [18].2.5. The 8-MMMAS
The original 8-MMMAS was tested by Morisky et al.
[18] on a sample of hypertensive patients, and
the scale was reliable with good predictive validity
and sensitivity. Sensitivity and specificity of the
8-item scale were 93% and 53%, respectively [18].
The scale is a widely used and validated method
for assessing patient adherence/nonadherence
to a drug regimen. Highly adherent patients were
identified with a score of 8 on the scale, medium
adherers with a score of 6 or <8, and low adherers
with a score of <6 [18]. Using a cutoff of 6, its sen-
sitivity in identifying low versus high adherers was
estimated to be 93% and the specificity was 53%
[18].
2.6. Statistical analysis
All data were analyzed using SPSS version 20 (IBM,
Corp., Atlanta, GA, USA). Bivariate and multivari-
ate (linear and logistic regressions) analyses wereTable 2 Lifestyle characteristics.
Variables
Smoking status
Nonsmoker
Smoker
Ex-smoker
Number of cigarettes/d
Regular sport
Yes
No
Frequency of practicing sport/wk
1–3
4–7
Doctor recommended a certain diet?
Yes
No
Do you follow this diet?
No/sometimes
Yes
Do you eat a lot of salt?
No
Some
Yes
Do you regularly measure your BP?
Yes
No
BP = blood pressure; SD = standard deviation.undertaken. The dependent variable for linear
regression was the medication adherence score,
which is a continuous variable ranging from 0 to
8, while for logistic regression it was the dichoto-
mized adherence score (based on a cutoff
point = 6). Only variables having p < 0.2 in bivariate
analysis were included in multivariate analysis. We
considered a 95% confidence interval and a value of
p < 0.05 to be statistically significant.
3. Results
3.1. Socio-demographic and lifestyle
characteristics
Two hundred and ten patients were approached,
agreed to participate (100%), and were included
in this study. Forty percent were males, with no
significant (p = 0.199) age difference between
males (60.65 ± 12.34) and females (58.44 ± 12.07).
The majority of the study population was married
(81%) and only 27.1% of the sample population is
employed (Table 1). Forty percent are smokers
and 69% of patients regularly measure their blood
pressure (Table 2).Mean ± SD/n (%)
102 (48.6)
84 (40)
24 (11.4)
9.904 ± 15.506
67 (31.9)
143 (68.1)
31 (14.8)
36 (17.1)
197 (93.8)
13 (6.2)
92 (43.8)
118 (56.2)
137 (65.2)
34 (16.2)
39 (18.6)
145 (69)
65 (31)
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characteristics
The mean duration of hypertension was
7.65 ± 6.61 years and it was accompanied with other
comorbidities in 71.9% of cases. The mean DBP was
82.92 ± 9.41 mmHg, the mean SBP was
139.40 ± 18.56 mmHg, and 62.9% of the cases were
classified as having controlled BP. The average num-
ber of medications taken by patients was approxi-
mately four different medications/day (4.28 ± 2.71)
and, specifically, the mean number of antihyperten-
sive medications prescribed was 1.45 ± 0.68.Table 3 Health status and medication-related characteristics
Variables
Systolic blood pressure
Diastolic blood pressure
Duration of hypertension (y)
Uncontrolled BP
Controlled BP
Family history of hypertension
Yes
No
Presence of comorbidities
Yes
No
Number of comorbidities
Total number of medications
Number of antihypertensive medications
Pharmacological category of antihypertensive medications
Beta-blockers
Calcium channel blockers
ACEi/ARBs
Diuretics
Combination drug
Dosing frequency/d
Once daily
Twice daily
Three times daily
Do you experience any side effects related to antihyperten
Yes
No
Do you experience any complications related to hypertens
Yes
No
Do you take any OTC medications?
Yes
No
ACEi = angiotensin-converting-enzyme inhibitor; ARB = angiotensin
counter; SD = standard deviation.Regarding pharmacological classes, the most widely
prescribed type of antihypertensive medications
was beta-blockers (BB) at 62.9% (Table 3).
3.3. Relationship with healthcare provider
When asked, 36.7% of patients admitted that they
postpone physician appointments. Also, results
showed that a high percentage (89.5%) of hyper-
tensive patients know the normal BP reading
(120/80 mmHg) and that the most commonly
reported cause of stopping medication was forget-
fulness at 21.4% (Table 4)..
Mean ± SD/n (%)
139.404 ± 18.560
82.928 ± 9.414
7.650 ± 6.617
78 (37.1)
132 (62.9)
185 (88.1)
25 (11.9)
185 (88.1)
59 (28.1)
1.28 ± 1.077
4.285 ± 2.711
1.457 ± 0.685
132 (62.9)
48 (22.9)
78 (37.1)
36 (17.1)
63 (30)
77 (36.7)
82 (39)
51 (24.3)
sive medications?
28(13,3)
182(86,7)
ion?
67(31.9)
143(68.1)
77 (36.7)
133 (63.3)
II receptor blockers; BP = blood pressure; OTC = over-the-
162 M. Yassine et al.3.4. Adherence patterns
The mean 8-MMMAS score was 6.59 ± 2.0, with mini-
mum and maximum scores of 0 and 8, respectively.
Following classification, 50.5% showed high adher-
ence, 27.1% medium adherence, and 22.4% low
adherence. These results were modified to 77.6%
high adherence and 22.4% low adherence following
dichotomization based on a cutoff point <6 (Table 5).
3.5. Factors associated with
antihypertensive medication adherence
The association of different variables with adher-
ence status was investigated using both bivariate
and multivariate analyses. Variables that showed
significant association in the bivariate analysis
included following a recommended diet, adding
salt to food, having a controlled/uncontrolled BP,
taking BBs as an antihypertensive medication, tak-
ing any over-the-counter (OTC) medications, post-
poning medical appointments, understanding how
to take medications, knowing normal BP value,Table 4 Relationship with healthcare provider.
Variables
Do you consult a physician about your disease/treatment?
No
Yes
Frequency of physician visit (mo)
Do you postpone your doctor appointment?
No
Yes
Does the doctor explain how to take medications?
No
Yes
Do you understand how to take your medication?
No
Yes
Does the doctor explain your disease?
No
Yes
Do you know the normal BP value?
No
Yes
Reason for stopping medication
Did not stop
Forget
Drug cost
Complicated regimen
Side effects
Controlled BP
BP = blood pressure; SD = standard deviation.facing different reasons to stop taking medica-
tions, value of SBP and DBP, and number of
cigarettes/day (Table 6).
Linear regression results indicated that stopping
medications due to forgetfulness has the greatest
impact on adherence score (standardized
b = 0.481), decreasing it by approximately 2 points
(p < 0.01). Similarly, stopping medication due to
feeling that the disease is under control
(p < 0.01), the drug regimen is too complicated
(p < 0.01), experiencing side effects (p < 0.01), or
drug cost (p < 0.01) were associated with a
decrease in adherence score by a range of approxi-
mately 1–3 points. Only understanding how to take
medications (p < 0.01) and having a combination
drug (p < 0.023) were shown to improve adherence
score (Table 7). Results of logistic regression
showed that patients taking calcium channel block-
ers (CCB) or knowing the normal BP value were
three to five times more adherent than those tak-
ing other types of medication or not knowing the
normal BP value (ORa = 3.08, 95% confidence inter-
val [1.12; 8.50], p = 0.030 and ORa = 4.95, 95%Mean ± SD/n (%)
27 (12.9)
183 (87.1)
6.490 ± 7.744
133 (63.3)
77 (36.7)
6 (2.9)
204 (97.1)
9 (4.3)
201 (95.7)
17 (8.1)
193 (91.9)
22 (10.5)
188 (89.5)
140 (66.7)
45 (21.4)
11 (5.2)
3 (1.4)
3 (1.4)
8 (3.8)
Table 5 Percentages of 8-MMMAS answers and adherence scores.
Question Yes (%) No (%)
1- Do you sometimes forget to take your pills? 30.5 69.5
2- People sometimes miss taking
their medication for reasons other than forgetting.
Thinking over the past two weeks, were there
any days when you did not take your medicine?
16.7 83.3
3- Have you ever cut back or stopped taking
your medication without telling your doctor,
because you felt worse when you took it?
11 89
4- When you travel or leave home, do you sometimes
forget to bring along your medication?
23.8 76.2
5- Did you take your medication yesterday? 91.4 8.6
6- When you feel like your disease is under control,
do you sometimes stop taking your medicine?
11 89
7- Taking medication every day is a real inconvenience
for some people. Do you ever feel hassled
about sticking to your treatment plan?
12.9 87.1
Sometimes/often/always Never/rarely
8- How often do you have difficulty remembering
to take all of your medication?
26.2 73.8
Mean SD Median Range (min–max)
8-MMMAS Score 6.595 2.005 8 0–8
High adherence (=8) Medium adherence (6–7) Low adherence (0–5)
8-MMMAS Classes (%) 50.5 27.1 22.4
Adherent Nonadherent
Dichotomous 8-MMMAS (%) 77.6 22.4
8-MMMAS = 8-items modified Morisky medication adherence scale; SD = standard deviation.
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Table 6 Variables associated with adherence score.
Variables Mean 8-MMMAS p
Do you follow the recommended diet?
No/sometimes 6.119 0.003
Yes 6.966
Do you eat a lot of salt?
No 6.875 <0.001
Some 7.294
Yes 5
Controlled BP
Uncontrolled 6.115 0.011
Controlled 6.878
Taking beta-blockers 6.348 0.011
Taking combination drug 7 0.023
Do you take any OTC medications?
No 6.842 0.019
Yes 6.168
Do you postpone your doctor appointment?
No 7.037 <0.001
Yes 5.831
Do you understand explanation about your medication provided by your doctor?
No 4.222 0.034
Yes 6.701
Do you know the normal BP value?
No 5.727 0.032
Yes 6.696
Reason for stopping taking the medications
Did not stop 7.471 <0.001
Forget 4.777
Drug cost 5.818
Complicated regimen 4
Side effects 5.666
Controlled BP 3.875
Number of cigarettes/day – 0.005
Systolic blood pressure – 0.006
Diastolic blood pressure – <0.001
8-MMMAS = 8-items modified Morisky medication adherence scale; BP = blood pressure; OTC = over-the-counter.
164 M. Yassine et al.confidence interval [1.52; 16.13], p = 0.008,
respectively) (Table 8).
4. Discussion
The objective of our study was to estimate the
prevalence of nonadherence to antihypertensive
medication in Lebanese hypertensive patients and
to evaluate what factors predict and constitute a
barrier toward good medication adherence. The
overall percentage of adherent hypertensive
patients was 77.6%, greater than that reported by
the WHO for other developing countries, such as
Gambia (27%) [19], as well as Saudi Arabia (53%)[12] and China (65.1%) [7]. However, it is slightly
greater than the adherence rate (71.6%) of patients
in the Unites States according to 8-MMMAS [20].
Cultural factors, such as cultural health perception
of hypertension, self-care behaviors, and social
support, could explain variations in adherence
rates among different populations.
Sociodemographic factors were not associated
with any variation in adherence levels. This is sim-
ilar to findings from a study from Brazil [21], while
other studies have shown different results. Younger
patients and males [22] were found to be less
adherent, while another study showed the opposite
[12]. Additionally, poor socioeconomic status,
Table 7 Multivariate analysis and linear regression model.
Variables Unstandardized b 95% CI p
Forgot to take drugsa 2.346 2.852; 1.841 <0.001
Feeling BP is controlleda 3.338 4.378; 2.299 <0.001
DBP 0.033 0.055; 0.012 0.003
High drug costa 1.308 2.223; 0.394 0.005
Complicated drug regimena 2.852 4.530; 1.174 0.001
Understand how to take medications 1.536 0.541; 2.531 0.003
1,000,000–2,000,000 0.547 0.137; 0.957 0.009
Stop due to SEa 2.386 4.068; 0.705 0.006
Postpone physician appointments 0.525 0952; 0.098 0.016
Combination drug 0.514 0.073; 0.956 0.023
BP = blood pressure; CI = confidence interval; DBP = diastolic blood pressure.Dependent variable: Morisky score.
Model statistics: adjusted R2 = 0.513/p-value of the model ANOVA < 0.001.
a Reasons to stop medications (categorical variable).
Table 8 Multivariate analyses and logistic regression model.
Variables Adjusted odds ratio (Exp b) 95% CI p
Duration of cigarette smoking 0.968 0.944; 0.992 0.010
Salt (1)a 2.282 0.593; 8.787 0.230
Salt (2)a 0.118 0.047; 0.297 <0.001
Taking CCB 3.080 1.116; 8.501 0.030
Postpone physician visits 0.245 0.110; 0.543 0.001
Know normal BP value 4.948 1.517; 16.134 0.008
BP = blood pressure; CCB = calcium channel blockers; CI = confidence interval; DBP = diastolic blood pressure.Dependent variable:
dichotomized Morisky score.Omnibus test p-value < 0.001/Hosmer–Lemeshow test p-value = 0.986.
Nagelkerke R2 = 0.362/Overall predicted percentage = 83.7%.
a Salt amount (categorical variable)/reference group: no salt added.
Adherence in hypertensive patients 165illiteracy, and unemployment were estimated to be
important risk factors for poor adherence [23].
Following a physician-recommended diet
reflects an aspect of a management plan that all
adherers complied with, in addition to taking med-
ication. This perhaps indicates a level of awareness
that hypertension management is an integrated
plan, wherein pharmacological treatment is com-
plementary to the nonpharmacological.
Several studies show a strong linkage between
medication adherence and BP control. Controlled
levels of SBP and DBP were most prominent among
adherent patients according to studies done in
Brazil [21] and the United States [18,20]. Our find-
ings match these, wherein association between
adherence levels and controlled BP and inverse cor-
relationbetweenadherence scores andboth SBPand
DBP affirm the cited results. This can be attributed
to the mutual association between better outcomes
of the treatment offering the patient satisfaction
and creating strong motivation toward treatment
and bad outcomes (uncontrolled BP) making the
patient hopeless and lowering satisfaction, resulting
in treatment termination. Better adherence tomed-
ication can consequently lead to improved clinical
outcomes, one of which is controlled BP.Surprisingly, the number of antihypertensive
medications was not related to adherence behav-
iors. This is consistent with findings from China
[7] and contrary to a study undertaken in France
[24]. Our study demonstrated that taking a
combination of antihypertensive drugs rather than
multiple single drugs may improve adherence
levels. However, the opposite is true when taking
many OTC medications concurrently with hyper-
tension medications. As a result, complicated drug
regimens, commonly accepted as a reason for poor
adherence [25,26], should be simplified by fewer
daily doses of antihypertensive drugs, monothera-
pies (preferably combination dosages), and fewer
changes in antihypertensive medications for better
adherence outcomes.
In crude analyses, only patients on BBs were less
adherent than others, possibly attributed to the
fact that in Lebanon, most BBs are available in a
single form and not in combinations. This is in addi-
tion to side effects associated with BBs, specifically
hypotension and sexual impotence.
After adjustment for other factors in multivari-
ate analyses, CCBs were found to improve adher-
ence in hypertensive patients, similar to a study
carried out in the Unites States using 8-MMMAS
166 M. Yassine et al.[27]. Patients for whom CCBs are recommended
are generally at high risk of coronary disease, dia-
betes, or have higher BP levels [1]. Thus, patients
taking these drugs may have a more severe disease
and comorbidities reinforcing the importance of
medication adherence. Furthermore, significant
improvements of depressive symptoms in patients
randomized for dosages of verapamil versus
atenolol suggest positive mood-related effects
associated with this CCB [28], which may impact
adherence. Finally, the reduced variation in SBP
observed in patients taking CCBs [29] may result
in more controlled BP levels over time and thus
better adherence.
A good relationship between patients and their
healthcare providers, as well as proper counseling,
can affect adherence levels in hypertensive patients
[18,20]. One of the aspects of a good patient–
healthcare provider relationship is adhering to
physician appointments and understanding counsel-
ing regarding treatment and disease, which can
improve adherence outcomes. For example, our
study demonstrated a strong association between
adherence scores and patient knowledge of normal
BP values, understanding physician explanations
regarding treatment, and postponing physician vis-
its. Patients attending medical appointments may
positively impact drug treatment adherence, given
that frequent patient attendance at the clinic may
offer reduced BP levels by providing motivation
and improving attitudes that contribute to reduc-
tion of arterial hypertension, better pressure-level
monitoring, and increased access to information
related to treatment and disease.
Forgetting to take drugs and drug cost were the
most commonly reported barriers to medication
adherence. Our findings are in line with those of
a study from Pakistan [16]. Appropriate measures
should be taken to enhance patient memory,
including planning to take medications in conjunc-
tion with certain activities, such as eating meals,
and recommending the use of pill boxes that orga-
nize the process of medication intake. Physicians
can also prescribe generic medications when drug
cost is a barrier to adherence.
To our knowledge, this is the first study carried
out in Lebanon analyzing adherence to antihyper-
tensive medications among Lebanese hypertensive
patients. Many factors have been identified as pos-
sible barriers to adherence leading to poor treat-
ment outcomes.
Several limitations to our study can be
addressed here. As mentioned, given that patients
having co-existing illnesses were not included,
some of our results may not be purely indicativeof the characteristics of all hypertensive patients.
Hence, the extent of generalization is limited.
Self-reporting was used as the only method of
measuring adherence, which has potential
disadvantages concerning recall bias and eliciting
only socially-acceptable responses. Given these
possibilities, adherence levels among participants
may be overestimated. Additionally, single BP
readings were used to classify patients into con-
trolled and uncontrolled hypertension groups,
which may increase classification bias. Also, we
did not account for the ‘‘white-coat’’ effect while
making these classifications. This implies that a
subject demonstrating ‘‘normal’’ BP levels when
measured outside of a physician office may exhibit
levels in the hypertensive range when levels are
measured within a physician office [30]. Similarly,
we did not account for ‘‘white-coat’’ adherence,
which is defined as improving medication-taking
behavior shortly before and after an appointment
with a healthcare provider [13]. Multiple compar-
isons may give rise to ‘‘false’’ positive associations
so that a more skeptical assessment of the
obtained associations is needed.
5. Conclusion
Our study highlights several factors that may
impact adherence levels in Lebanese hypertensive
patients either by improving adherence though
understanding how to take medications, knowing
normal BP value, or taking CCBs, or decreasing
adherence through high drug costs, forgetfulness,
or complicated drug regimens.
We recommended implementing educational
campaigns to increase awareness about hyperten-
sion risk factors, complications, and treatment.
Patient–healthcare provider factors, such as
patient education and counseling, developing a
good healthcare provider–patient relationship,
and innovating new ways to help patients remem-
ber to take their medications should be
emphasized.
Conflicts of interest
There are no conflicts of interest to disclose.
References
[1] Chobanian AV, Bakris GL, Black HR, Cushman WC, Green
LA, Izzo Jr JL, et al. Seventh report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure. Hypertension
2003;42:1206–52.
Adherence in hypertensive patients 167[2] Kearney PM, Whelton M, Reynolds K, Whelton PK, He J.
Global burden of hypertension: analysis of worldwide data.
Lancet 2005;365:217–23.
[3] Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K,
Ezekowitz MD, et al. Forecasting the future of cardiovascular
disease in the United States: a policy statement from the
American Heart Association. Circulation 2011;123:933–44.
[4] Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA,
Higgins M, et al. Prevalence of hypertension in the US adult
population. Results from the Third National Health and
Nutrition Examination Survey, 1988–1991. Hypertension
1995;25:305–13.
[5] Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE,
Wattigney WA. The Bogalusa Heart Study. Association
between multiple cardiovascular risk factors and
atherosclerosis in children and young adults. N Engl J Med
1998;338:1650–6.
[6] Thompson DW, Furlan AJ. Clinical epidemiology of stroke.
Neurol Clin 1996;14:309–15.
[7] Lee GK, Wang HH, Liu KQ, Cheung Y, Morisky DE, Wong MC.
Determinants of medication adherence to antihypertensive
medications among a Chinese population using Morisky
Medication Adherence Scale. PLoS One 2013;8:e62775.
[8] Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli
S, Joffres MR, et al. Hypertension treatment and control in
five European Countries, Canada, and the United States.
Hypertension 2004;43:10–7.
[9] Sabate E. Adherence to long-term therapies: evidence for
action. Geneva: World Health Organization. http://www.
who.int/chronic_conditions/en/adherence_report.pdf;
2003 (accessed March 1, 2014).
[10] Mant J, McManus RJ. Does it matter whether patients take
their antihypertensive medication as prescribed? The com-
plex relationship between adherence and blood pressure
control. J Hum Hypertens 2006;20:551–3.
[11] Stewart RB, Caranasos GJ. Medication compliance in the
elderly. Clin Pharmacol Ther 1989;73:1551–63.
[12] Khalil SA, Elzubier AG. Drug compliance among hyperten-
sive patients in Tabuk, Saudi Arabia. J Hypertens 1997;15:561–5.
[13] Osterberg L, Blaschke T. Drug therapy: adherence to
medication. N Engl J Med 2005;353:487–97.
[14] Payne KA, Esmond-White S. Observational studies of anti-
hypertensive medication use and compliance. is drug
choice a factor in treatment adherence? Curr Hypertens
Rep 2000;2:515–24.
[15] Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J.
Noncompliance with antihypertensive medications: the
impact of depressive symptoms and psychosocial factors.
J Gen Intern Med 2002;17:504–11.
[16] Almas A, Hameed A, Ahmed B, Islam M. Compliance to antihy-
pertensive therapy. J Coll Physicians Surg Pak 2006;16:23–6.
[17] Charan J, Biswas T. How to calculate sample size for
different study designs in medical research? Indian J
Psychol Med 2013;35:121–6.[18] Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive
validity of a medication adherence measure in an outpa-
tient setting. J Clin Hypertens (Greenwich)
2008;10:348–54.
[19] van der Sande MA, Milligan PJ, Nyan OA, Rowley JT, Banya
WA, Ceesay SM, et al. Blood pressure patterns and cardio-
vascular risk factors in rural and urban Gambian commu-
nities. J Hum Hypertens 2000;14:489–96.
[20] Hyre AD, Krousel-Wood MA, Muntner P, Kawasaki L, DeSalvo
KB. Prevalence and predictors of poor antihypertensive
medication adherence in an urban health clinic setting. J
Clin Hypertens (Greenwich) 2007;9:179–86.
[21] Oliveira-Filho AD, Barreto-Filho JA, Neves SJ, Neves DP.
Association between the 8-item Morisky Medication
Adherence Scale (MMAS-8) and blood pressure control.
Arq Bras Cardiol 2012;99:649–58.
[22] Marentette MA, Gerth WC, Billings DK, Zarnke KB.
Antihypertensive persistence and drug class. Can J Cardiol
2002;18:649–56.
[23] Saounatsou M, Patsi O, Fasoi G, Stylianou M, Kavga A,
Economou O, et al. The influence of the hypertensive
patients education in compliance with their medication.
Public Health Nurs 2001;18:436–42.
[24] Korb-Savoldelli V, Gillaizeau F, Pouchot J, Lenain E, Postel-
Vinay N, Plouin PF, et al. Validation of a French version of
the 8-item Morisky medication adherence scale in hyper-
tensive adults. J Clin Hypertens (Greenwich)
2012;14:429–34.
[25] Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A,
Mittmann N, et al. Relationship between daily dose fre-
quency and adherence to antihypertensive pharmacother-
apy evidence from a meta-analysis. Clin Ther
2002;24:302–16.
[26] George J, Phun YT, Bailey MJ, Kong DC, Stewart K.
Development and validation of the medication regimen
complexity index. Ann Pharmacother 2004;38:1369–76.
[27] Krousel-Wood M, Joyce C, Holt E, Muntner P, Webber LS,
Morisky DE, et al. Predictors of decline in medication
adherence: results from the cohort study of medication
adherence among older adults. Hypertension
2011;58:804–10.
[28] Ried LD, Tueth MJ, Handberg E, Kupfer S, Pepine CJ. A
Study of Antihypertensive Drugs and Depressive Symptoms
(SADD-Sx) in patients treated with a calcium antagonist
versus an atenolol hypertension Treatment Strategy in the
International Verapamil SR-Trandolapril Study (INVEST).
Psychosom Med 2005;67:398–406.
[29] Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of
antihypertensive-drug class on interindividual variation in
blood pressure and risk of stroke: a systematic review and
metaanalysis. Lancet 2010;375:906–15.
[30] Pickering TG, James JD, Boddie C, Harshfield GA, Blank S,
Laragh JH. How common is white coat hypertension? JAMA
1988;259:225–8.ScienceDirect
Available online at www.sciencedirect.com
